Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Opportunities to Optimize Cancer Policies Panel Discussion

Opening Session Panel Discussion

Dec

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Opportunities to Optimize Cancer Policies Panel Discussion

Opening Session Panel Discussion

Flipped Nivolumab/Ipilimumab Dosing Improves Outcomes in Advanced Melanoma

Tanning Bed Exposure and Melanoma Risks

FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma

HER2-Positive Breast Cancer FDA Approves T-DXd Plus Pertuzumab

Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers